Compare Dollar General Corp. (DG) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Pfizer Inc — how do they compare? Dollar General Corp. trades at $127.23 (market cap $27.42B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 5.8× Dollar General Corp.'s market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Pfizer Inc for 158 Days on average.
| DG | PFE | |
|---|---|---|
Market Cap | $27.42B | $158.56B |
Volume | 2,291,517 | 44,138,282 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $29.02 |
52-Week Low | $95.94 | $23.67 |
Typical Hold Time | 59 Days | 158 Days |
Enterprise Value | $41.60B | $210.06B |
Dividend Yield | 1.9% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $124.27, up 1.73% today, with a bullish technical signal from moving averages and strong analyst support (55.77% buy ratings). Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.48 exceeding the $2.01 estimate. The company benefits from tariff refunds boosting margins and is expanding delivery via Instacart and scaling its DG Media Network for growth.
The outlook is positive, with a consensus price target of $137.27 implying ~10% upside. Key opportunities include margin recovery initiatives and value-focused merchandising, but risks persist from consumer pressure and competitive discount retail dynamics. Net cash flow improved to $395 million in 2025, though profit margins have narrowed from 7.01% in 2022 to 2.77% in 2025.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
